Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats

Drug Metabolism and Disposition

Volumn 25, Issue 2, 1997, Pages 228-242

  Chang, Mayland ^a   Sood, Virendra K ^b   Wilson, Gracella J ^b   Kloosterman, David A ^b   Sanders, Phillip E ^b   Hauer, Michael J ^b   Fagerness, Paul E ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6' HYDROXYDELAVIRDINE; DELAVIRDINE; DESPYRIDINYLDELAVIRDINE; DRUG METABOLITE; INDOLE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; BILE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAVIRDINE; FECES; FEMALE; HIV-1; INDOLES; MALE; MASS SPECTROMETRY; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE INHIBITORS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031037656     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. T. J. Dueweke, S. M. Poppe, D. L. Romero, S. M. Swaney, A. G. So, K. M. Downey, I. W. Althaus, F. Reusser, M. Busso, L. Resnick, D. Mayers, J. Lane, P. A. Aristoff, R. C. Thomas, and W. G. Tarpley: U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 37, 1127-1131 (1993).
2. Y. N. Vaishnav and F. Wong-Staal: The biochemistry of AIDS. Annu. Rev. Biochem. 60, 577-630 (1991).
3. H. Mitsuya, R. Yarchoan, and S. Broder: Molecular targets for AIDS therapy. Science 249, 1533-1544 (1990).
4. E. De Clercq: Targets and strategies for the antiviral chemotherapy of AIDS. Trends Pharmacol. Sci. 11, 198-205 (1990).
5. M. A. Fischl, D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, R. T. Schooley, G. G. Jackson, D. T. Durack, D. King, and the AZT Collaborative Working Group: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N. Engl. J. Med. 317, 185-191 (1987).
6. R. Yarchoan, H. Mitsuya, C. E. Myers, and S. Broder: Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N. Engl. J. Med. 321, 726-738 (1989).
7. R. Yarchoan, H. Mitsuya, R. V. Thomas, J. M. Pluda, N. R. Hartman. C.-F. Perno, K. S. Marczyk, J. P. Allain, D. G. Johns, and S. Broder: In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science 245, 412-417 (1989).
8. J. S. Lambert, M. Seidlin, R. C. Reichman, C. S. Plank, M. Laverty, G. D. Morse, C. Knupp, C. McLaren, C. Pettinelli, F. T. Valentine, and R. Dolin: 2′,3′-Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N. Engl. J. Med. 322, 1333-1340 (1990).
9. T. P. Cooley, L. M. Kunches, C. A. Saunders, J. K. Ritter, C. J. Perkins, C. McLaren, R. P. McCaffrey, and H. A. Liebman: Once-daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a phase I trial. N. Engl. J. Med. 322, 1340-1345 (1990).
10. R. Yarchoan, R. V. Thomas, J.-P. Allain, N. McAtee, R. Dubinsky, H. Mitsuya, T. J. Lawley, B. Safai, C. E. Myers, C. F. Perno, R. W. Klecker, R. J. Wills, M. A. Fischl, M. C. McNeely, J. M. Pluda, M. Leuther, J. M. Collins, and S. Broder: Phase I studies of 2′-3′dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1, 76-81 (1988).
11. S. A. Riddler, R. E. Anderson, and J. W. Mellors: Antiretroviral activity of stavudine (2′,3′-didehydro-3′-deoxythymidine, d4T). Antiviral Res. 27, 189-203 (1995).
12. D. D. Richman, M. A. Fischl, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, M. S. Hirsch, G. G. Jackson, D. T. Durack, S. Nusinoff-Lehrman, and the AZT Collaborative Working Group: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N. Engl. J. Med. 317, 192-197 (1987).
13. H. König, E. Behr, J. Löwer, and R. Kurth: Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type I reverse transcriptase and DNA polymerase gamma. Antimicrob. Agents Chemother. 33, 2109-2114 (1989).
14. B. A. Larder and S. D. Kemp: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246, 1155-1158 (1989).
15. B. A. Larder, G. Darby, and D. D. Richman: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731-1734 (1989).
16. P. Kellam, C. A. B. Boucher, and B. A. Larder: Fifth mutation in a human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. U.S.A. 89, 1934-1938 (1992).
17. M. H. St. Clair, J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder: Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253, 1557-1559 (1991).
18. R. Pauwels, K. Andries, J. Desmyter, D. Schols, M. J. Kukla, H. J. Breslin, A. Raeymaeckers, J. Van Gelder, R. Woestenborghs, J. Heykants, K. Schellekens, M. A. C. Janssen, E. De Clercq, and P. A. J. Janssen: Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343, 470-474 (1990).
19. V. J. Merluzzi, K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. Wu, C.-K. Shih, K. Eckner, S. Hattox, J. Adams, A. S. Rosehthal, R. Faanes, R. J. Eckner, R. A. Koup, and J. L. Sullivan: Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250, 1411-1413 (1990).
20. M. E. Goldman, J. H. Nunberg, J. A. O'Brien, J. C. Quintero, W. A. Schleif, K. F. Freund, S. Lee Gaul, W. S. Saari, J. S. Wai, J. M. Hoffman, P. S. Anderson, D. J. Hupe, E. A. Emini, and A. M. Stern: Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. U.S.A. 88, 6863-6867 (1991).
21. J. Balzarini, M.-J. Pérez-Pérez, A. San-Felix, D. Schols, C.-F. Perno, A.-M. Vandamme, M.-J. Camarasa, and E. De Clercq: 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 89, 4392-4396 (1992).
22. H. Tanaka, M. Baba, H. Hayakawa, T. Sakamaki, T. Miyasaka, M. Ubasawa, H. Takashima, K. Sekiya, I. Nitta, S. Shigeta, R. T. Walker, J. Balzarini, and E. De Clercq: A new class of HIV-1 specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5-or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). J. Med. Chem. 34, 349-357 (1991).
23. R. Pauwels, K. Andries, Z. Debyser, P. Van Daele, D. Schols, P. Stoffels, K. De Vreese, R. Woestenborghs, A.-M. Vandamme, C. G. M. Janssen, J. Anne, G. Cauwenbergh, J. Desmyter, J. Heykants, M. A. C. Janssen, E. De Clercq, and P. A. J. Janssen: Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 90, 1711-1715 (1993).
24. H. Maruenda and F. Johnson: Design and synthesis of novel inhibitors of HIV-1 reverse transcriptase. J. Med. Chem. 38, 2145-2151 (1995).
25. Y. Hanasaki, H. Watanabe, K. Katsuura, H. Takayama, S. Shirakawa, K. Yamaguchi, S. Sakai, K. Ijichi, M. Fujiwara, K. Konno, T. Yokota, S. Shigeta, and M. Baba: Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors. J. Med. Chem. 38, 2038-2040 (1995).
26. P. G. Wyatt, R. C. Bethell, N. Cammack, D. Charon, N. Dodic, B. Dumaitre, D. N. Evans, D. V. S. Green, P. L. Hopewell, D. C. Humber, R. B. Lamont, D. C. Orr, S. J. Plested, D. M. Ryan. S. L. Sollis, R. Storer, and G. G. Weingarten: Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase. J. Med. Chem. 38, 1657-1665 (1995).
27. D. L. Romero, R. A. Morge, M. J. Genin, C. Biles, M. Busso, L. Resnick, I. W. Althaus, F. Reusser, R. C. Thomas, and W. G. Tarpley: Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1-methylethyl)amino]- pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate. J. Med. Chem. 36, 1505-1508 (1993).
28. L. M. Demeter, R. W. Shafer, M. Para, G. Morse, W. W. Freimuth, and T. Merigan: Delavirdine (DLV) susceptibility of HIV-1 isolates obtained from patients receiving DLV monotherapy (ACTG 260). Fourth International HIV Drug Resistance Workshop, Sardinia, Italy, July 6-9, 1995 (abstr. 23).
29. K. T. Chong, P. J. Pagano, and R. R. Hinshaw: Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob. Agents Chemother. 38, 288-293 (1994).
30. P. K. Peterson, G. Gekker, S. Hu, and C. C. Chao: Anti-human immunodeficiency virus type 1 activities of U-90152 and U-75875 in human brain cell cultures. Antimicrob. Agents Chemother. 38, 2465-2468 (1994).
31. P. J. Pagano and K. T. Chong: In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha. J. Infect. Dis. 171, 61-67 (1995).
32. A. Bax, R. H. Griffey, and B. L. Hawkins: Correlation of proton and nitrogen-15 chemical shifts by multiple quantum NMR. J. Magn. Reson. 55, 301-315 (1983).
33. A. J. Shaka, P. B. Barker, and R. Freeman: Computer-optimized decoupling scheme for wideband applications and low-level operation. J. Magn. Reson. 64, 547-552 (1985).
34. 1H spin-spin coupling constants in proteins. Biochem. Biophys. Res. Commun. 113, 967-974 (1983).
35. A. F. Poile and R. D. Conlon: Numerical spectroscopy: absorbance index technique and algorithm for qualitative analysis in liquid chromatography. J. Chromagr. 204, 149-152 (1981).
36. V. K. Sood, D. A. Kloosterman, P. E. Sanders, M. J. Hauer, J. J. Vrbanac, and M. Chang: Metabolism of the reverse transcriptase inhibitor delavirdine: identification of novel N-acetylglucosamine and pyridinol sulfate conjugates. Fourth International Meeting of the International Society for the Study of Xenobiotics, Seattle, WA, August 27-31, 1995 (abstr. 137).